Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

C-H LinP-K ChenS-H WangHsien-Yuan Lane

Published in: Journal of psychopharmacology (Oxford, England) (2019)

Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

Keyphrases

squamous cell carcinoma
placebo controlled
double blind
phase iii
study protocol
phase ii
clinical trial
randomized controlled trial
open label
combination therapy
radiation therapy
phase ii study
physical activity
rectal cancer
cognitive impairment